Inclinix, Inc., a contract research organization (CRO) specializing in clinical trial enrollment solutions, announces the expansion of its in-field Regional Recruitment Manager (RRM) team, including international and multi-lingual professionals.
WILMINGTON, N.C., Oct. 15 /PRNewswire/-Inclinix, Inc., a contract research organization (CRO) specializing in clinical trial enrollment solutions, announces the expansion of its in-field Regional Recruitment Manager (RRM) team, including international and multi-lingual professionals. In response to the emergent demand for enrollment experts in the field to assist with difficult to enroll studies, Inclinix has increased the team by 200%.
Regional Recruitment Managers are enrollment experts, clinically experienced across multiple therapeutic areas and trained to develop and execute site-specific patient recruitment strategies. These professionals identify patient recruitment opportunities and challenges both within the site and its adjacent community. In addition to providing hands-on resources to site staff to identify potential study participants, RRMs serve an important role in the continuing education and promotion of studies within healthcare networks supporting and surrounding the site. This unique outreach drives study participation while educating healthcare providers and other patient advocates.
Tobin Geatz, President and CEO of Inclinix says, "the industry is demanding new and innovative strategies to solve the day-to-day challenges of patient recruitment." Geatz further states, "our sponsors know our reputation as experts in patient recruitment, and have easily adopted our Regional Recruitment Managers as a solution to make their sites more productive."
Regional Recruitment Managers are critical to successful enrollment, particularly in trials requiring special populations, low incidences of disease, or in difficult-to-enroll trials where traditional recruitment tactics may be less effective. In a recent study of a special population, RRMs increased enrollment by 60% over sites not supported with RRMs. On average, sites supported with RRMs exceed monthly screening goals and contribute to successful enrollment milestones.
Inclinix clients have benefited from successful programs in therapeutic areas including congestive heart failure, pediatric hypertension,
post-operative pain and pre-term labor. With the expanded Regional Recruitment Manager team, Inclinix will steadily pursue enrollment challenges that cannot be met by traditional patient recruitment methods.
About Inclinix
Inclinix, Inc. is a CRO specializing in customized Phase I-IV clinical trial enrollment solutions for global pharmaceutical, biotechnology, and medical device organizations. Clients benefit from ten years of experience in multiple therapeutic areas, as well as leading edge technologies that meet the challenge of clinical development from feasibility through compliance. In addition, Inclinix provides strategic medical marketing communications and adherence services to the healthcare industry.
For more information, visit www.inclinix.com.
SOURCE Inclinix, Inc.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.